High-grade Serous Ovarian Cancer
📧 Sign up to get email alerts when something new happens for High-grade Serous Ovarian Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-06-04Clinical Trial Results: Alpelisib Plus Olaparib in Platinum-resistant/Refractory, High-grade Serous Ovarian Cancer, With no Germline BRCA Mutation Detected [Phase 3]
Phase 3 trial evaluating alpelisib plus olaparib in platinum-resistant/refractory high-grade serous ovarian cancer without germline BRCA mut…
-
CLINICAL_TRIALS research · 2026-04-24Clinical Trial Update: CtDNA as a Novel Biomarker of Treatment Efficacy in Patients With Ovarian Cancer
An ongoing clinical trial is evaluating circulating tumor DNA as a biomarker of treatment efficacy in patients with high-grade serous ovaria…
-
CLINICAL_TRIALS research · 2026-04-24Clinical Trial Update: Testing the Addition of Abemaciclib to Olaparib for Women With Recurrent Ovarian Cancer [Phase 1]
Phase 1 trial evaluating adding abemaciclib to olaparib in women with recurrent ovarian cancer, including high-grade serous and platinum-res…
-
CLINICAL_TRIALS research · 2026-04-23Clinical Trial Update: Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors [Phase 1, Phase 2]
A Phase 1/2 clinical trial of GTAEXS617 in adults with advanced solid tumors is currently recruiting. The study encompasses head and neck sq…
-
CLINICAL_TRIALS research · 2026-04-22Clinical Trial Update: A Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression [Phase 3]
Phase 3 trial to compare Azenosertib (ZN-c3) against investigator's choice chemotherapy in platinum-resistant high-grade serous ovarian, pri…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2026-04-15Clinical Trial Update: A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer [Phase 2]
Phase 2 clinical trial evaluating Azenosertib (ZN-c3) in platinum-resistant high-grade serous ovarian cancer and related fallopian tube or p…
-
CLINICAL_TRIALS trial_result · 2026-04-14Clinical Trial Update: Elements of Adaptive Immunity in Epithelial Ovarian Cancer
A completed clinical trial update examining elements of adaptive immunity in epithelial ovarian cancer, specifically the high-grade serous s…
-
CLINICAL_TRIALS trial_result · 2026-04-13Clinical Trial Update: Combination ATR and PARP Inhibitor (CAPRI) Trial With AZD6738 and Olaparib in Recurrent Ovarian Cancer [Phase 2]
The update notes the completion of the Phase 2 CAPRI trial evaluating the combination of AZD6738 (ceralasertib) and olaparib in recurrent hi…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan [Phase 1]
Phase 1 trial evaluating the safety, adverse events, and pharmacokinetics of Azirkitug alone or in combination with Budigalimab, Bevacizumab…
-
CLINICAL_TRIALS trial_result · 2026-04-13Clinical Trial Update: Upfront Systematic Tumour BRCA Testing in Patients With High Grade Serous or Endometrioid Ovarian, Fallopian Tube or Primary Peritoneal Cancer (HGSEC): The t-BRCA Study
This clinical trial update reports the completed status of the t-BRCA study evaluating upfront BRCA testing in patients with high-grade sero…
-
CLINICAL_TRIALS trial_result · 2026-04-09Clinical Trial Update: Safety, PK and Efficacy of AI-061 in Advanced Solid Tumors [Phase 1]
Phase 1 update reporting safety, pharmacokinetics, and preliminary efficacy data for AI-061 in advanced solid tumors across multiple indicat…
-
CLINICAL_TRIALS research · 2026-04-08Clinical Trial Update: A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors [Phase 1, Phase 2]
First-in-human dose-escalation and expansion trial of AZD8421 (alone or in combination) in selected advanced solid tumors, including ER+ HER…
-
CLINICAL_TRIALS research · 2026-04-07Clinical Trial Update: Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001) [Phase 1, Phase 2]
Genmab is conducting a Phase 1/2 clinical trial of Rinatabart Sesutecan for multiple advanced solid tumors; recruitment is ongoing.
-
CLINICAL_TRIALS research · 2026-03-31Clinical Trial Update: A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types [Phase 1]
IDEAYA Biosciences is conducting a Phase 1 study of IDE034 in adults with multiple locally advanced or metastatic solid tumors; the trial is…
-
CLINICAL_TRIALS research · 2026-03-18Clinical Trial Update: Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076) [Phase 3]
Phase 3 clinical trial evaluating Olvi-Vec in combination with platinum-doublet chemotherapy and Bevacizumab versus physician's choice of ch…
-
CLINICAL_TRIALS research · 2026-03-17Clinical Trial Update: Risk-reducing Strategies, Including Fimbriectomy, in Women With a Germline Mutation Predisposing to Ovarian or Pelvic Cancer [NA]
Clinical trial update on risk-reducing strategies, including fimbriectomy, for women with germline mutations predisposing to ovarian or pelv…
-
CLINICAL_TRIALS trial_result · 2026-03-13Clinical Trial Update: Alpelisib Plus Olaparib in Platinum-resistant/Refractory, High-grade Serous Ovarian Cancer, With no Germline BRCA Mutation Detected [Phase 3]
A Phase 3 trial of alpelisib plus olaparib for platinum-resistant/refractory high-grade serous ovarian cancer without germline BRCA mutation…
-
CLINICAL_TRIALS research · 2026-03-06Clinical Trial Update: Using Advanced Imaging Studies to Develop a Profile of High-grade Serous Ovarian Cancer [NA]
This Memorial Sloan Kettering-led trial update describes using advanced imaging to develop an imaging-based profile of high-grade serous ova…
-
CLINICAL_TRIALS trial_result · 2026-02-27Clinical Trial Update: ASTRA Study: Circulating Tumor Cells in Blood of Patients With High-Grade Serous Ovarian Cancer [NA]
The ASTRA study, which investigates circulating tumor cells in the blood of patients with high-grade serous ovarian cancer, has completed.
-
CLINICAL_TRIALS research · 2026-02-25Clinical Trial Update: Neoadjuvant Aitua (PD-1/CTLA-4 Bispecific) Plus Nab-Paclitaxel and Carboplatin for Advanced High-Grade Serous Ovarian Cancer [Phase 2]
This is a Phase 2 neoadjuvant trial evaluating Aitua, a PD-1/CTLA-4 bispecific, with nab-paclitaxel and carboplatin in advanced high-grade s…
-
CLINICAL_TRIALS research · 2026-02-12Clinical Trial Update: Immunotherapy Platform Study in Platinum Resistant High Grade Serous Ovarian Cancer [Phase 2]
A Phase 2 immunotherapy platform trial in platinum-resistant high-grade serous ovarian cancer is currently recruiting under the Canadian Can…
-
CLINICAL_TRIALS research · 2026-01-26Clinical Trial Update: Prognostic Value of (DHODH) Expression in (HGSOC): A Comparative Study Between Neoadjuvant and Adjuvant Chemotherapy Settings
This clinical trial explores whether DHODH expression serves as a prognostic biomarker in high-grade serous ovarian cancer and compares its …
-
CLINICAL_TRIALS trial_result · 2026-01-23Clinical Trial Update: Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR Inhibitor BBI-825, in Subjects With Tumors With Oncogene Amplifications [Phase 1]
A Phase 1 clinical trial update describes evaluation of BBI-355 (CHK1 inhibitor) in combination with BBI-825 (RNR inhibitor) for tumors with…
-
CLINICAL_TRIALS trial_result · 2026-01-23Clinical Trial Update: Exploration of DNA Methylation as a Marker for Early Detection of High Grade Serous Epithelial Ovarian Cancer
A Baylor Research Institute-led clinical trial evaluating DNA methylation as an early-detection marker for high-grade serous ovarian cancer …
-
CLINICAL_TRIALS trial_result · 2025-12-17Clinical Trial Update: A Study of Carboplatin and Paclitaxel Chemotherapy With Nivolumab With or Without Ipilimumab in Patients With Ovarian Cancer [Phase 1]
Phase 1 study evaluating carboplatin and paclitaxel chemotherapy with nivolumab, with or without ipilimumab, in ovarian cancer including hig…